CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
AMG 706 +1 moredrug
Likely dose
AMG 706 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00427349
NCT00427349Phase 2Completed
CompareCT.gov

A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group·interventional·Posted Jan 29, 2007·Updated Jul 5, 2023

In Brief

A Phase 2 clinical trial evaluating AMG 706 and octreotide for Gastrointestinal Carcinoid Tumor and 2 related conditions. Completed, enrolled 46 participants across 112 sites.

Detailed Summary

RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 29, 2007
Enrollment StartNov 7, 2008
Primary CompletionOct 1, 2014
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 19.4 years ago

Interventions

AMG 706drug

AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment

octreotidedrug

One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.